In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $3.90, marking a -4.88% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.51% for ...

It might take a while for this AI company to prove its worth, if it ever does so.

Recursion claims that its artificial-intelligence-backed drug discovery platform gets smarter each time it pinpoints a new drug candidate—which is why, even with several of those candidates already in ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $4.32, marking a -3.36% move from the previous day.

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the overlooked penny stocks to invest in. On January 12, Alec ...

Brings together Recursion’s scaled biology exploration and translational capabilities with Exscientia’s precision chemistry design and small molecule automated synthesis capabilities to create a ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...

Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...

Recursion Pharmaceuticals just acquired a pair of AI-related biotechs. This could bolster its drug discovery capabilities and better help its clients. But the stock is high-risk and requires a ...